This is the first dedicated peptide deep dive of The Energy Code — and it starts with arguably the most mitochondrial-centric peptide on the board: SS-31 (Elamipretide). Dr. Mike breaks down a new paper showing how SS-31 may protect neurons in Parkinson’s disease by competing with alpha-synuclein at lipid membranes, slowing toxic aggregation, restoring mitochondrial respiration, and even reducing alpha-synuclein cellular entry. You’ll also hear a key caution: SS-31 appears highly protective at moderate doses, but too much may flip the benefit into harm, reinforcing the “dose makes the medicine” rule in mitochondrial pharmacology.

(Educational content only, not medical advice.)

Article Discussed in Episode:

Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function

Key Quotes From Dr. Mike:

“The future of Parkinson’s therapy may not lie in cleaning up the mess, but rather in providing our neurons with a permanent molecular shield…”

“SS-31 acts as a molecular shield protecting the brain’s energy supply…”

“SS-31 acts as a molecular bouncer, physically evicting alpha-synuclein from lipid membranes…”

“SS-31 substantially prolonged the lag phase of aggregation, essentially stalling the clock on protein buildup.”

“These findings underscore the multifaceted protective role of SS-31 against mitochondrial dysfunction caused by alpha synuclein aggregation... SS-31 reversed this decline with a 10 micromolar dose…”

Key Points

SS-31 is framed as a mitochondria-first peptide: “restore impaired mitochondrial function” is the headline.
Parkinson’s pathology is presented as a cellular power failure inside dopaminergic neurons driven by alpha-synuclein toxicity.
SS-31 may act like a “molecular bouncer” — outcompeting alpha-synuclein for anionic lipid membranes and preventing harmful binding/folding.
The episode highlights the real-world complication: N-terminal acetylated alpha-synuclein (common in humans) embeds deeper and is harder to displace.
SS-31 appears to delay aggregation kinetics (longer “lag phase”) and shift aggregate morphology toward potentially less toxic off-pathway forms.
Mitochondrial function was assessed with a Seahorse mito stress test; SS-31 is described as restoring basal/max respiration (at a cited 10 μM dose).
Mechanistically, SS-31 is explained as:
1. Cardiolipin binding → supports OXPHOS efficiency/ATP output
2. ROS scavenging (tyrosine residue) → reduces oxidative damage
SS-31 may also reduce alpha-synuclein oligomer uptake by altering membrane electrostatics (less negative surface charge).
A major warning: very high concentrations (described as >100 μM) may trigger apoptosis / reduce viability.
Big-picture: SS-31 supports a “prevention-first” strategy — block the lipid–protein interaction upstream, rather than “cleaning up the mess” later.

Episode timeline

0:00–0:40 — Why peptides are the next major content focus; why SS-31 is the first peptide deep dive
0:40–3:55 — Paper intro + “SS-31 restores impaired mitochondrial function” framing; what the show will cover and why it matters
3:55–5:44 — Parkinson’s as mitochondrial “power failure”; alpha-synuclein as the driver; SS-31 as a BBB-permeable candidate
5:44–6:58 — Takeaway #1: SS-31 as a “molecular bouncer” displacing alpha-synuclein from membranes (dose-dependent)
6:58–8:16 — Takeaway #2: N-terminal acetylation makes alpha-synuclein “stickier” and harder to displace (real-human relevance)
8:16–9:40 — Takeaway #3: Aggregation kinetics + morphology shifts (stalling the “snowball”)
9:40–11:40 — Takeaway #4–#5: Respiration rescue + membrane/cell-entry effects; the dual mechanism (cardiolipin + ROS)
11:40–13:20 — Dose caution, wrap-up, and the “designer peptides” future-forward conclusion

Dr. Mike's #1 recommendations:

Deuterium depleted water: Litewater (code: DRMIKE)

EMF-mitigating products: Somavedic (code: BIOLIGHT)

Blue light blocking glasses: Ra Optics (code: BIOLIGHT)

Grounding products: Earthing.com

Stay up-to-date on social media:

Dr. Mike Belkowski:

BioLight Labs:

BioLight: